RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

As of mid-2009, this is what I thought:
<<Privately-held Galleon Pharma has licensed work done at the University of Virginia involving s-nitrosylating agents in the treatment of both RD and sleep apnea. They have an IV version of a currently marketed drug which they state showed benefit in a POC study, though no details have been made public. It is unclear whether they have succeeded in developing an oral version, and whether they are able to parse out the cardiovascular effects often seen with drugs operating via this mechanism.>>

Nothing much has changed. Since then they have continued to disclose almost nothing, and my information is that the drug they did the Phase IIa trial with would likely have some unacceptable cardiovascular side effects.

I'm not particularly concerned about Galleon. It's Biovail (at least for now) they'd in theory be challenging in RD. Neither this SA program nor BTG's have taken the high ground, so if Cortex's data is positive, they have just as good a shot as anyone.

NeuroInvestment